USE OF RILUZOLE PRODRUGS TO TREAT ATAXIAS
Disclosed are methods of treating ataxia by administering to a patient in need thereof a riluzole prodrug such as troriluzole. Pharmaceutical compositions and kits including the riluzole prodrugs are also disclosed.
1 - 18 . (canceled)
19 . A method of treating spinocerebellar ataxia type 3 in a patient, comprising releasing a therapeutically effective amount of riluzole into plasma of the patient in need of such treatment.
20 . The method of claim 19 , wherein riluzole is released for the period of 8 weeks to 48 weeks.
21 . The method of claim 19 , wherein the treatment provides an improvement in the patient's total SARA score of at least 0.8, or 0.9, or 1.0, or 1.1, or 1.2, or 1.3, or 1.4, or 1.5, or 1.6, or 1.7, or 1.8, or 1.9, or 2.0, or greater.
22 . A method for treating spinocerebellar ataxia type 3 in a patient, comprising contacting plasma of the patient in need of such treatment with a therapeutically effective amount of riluzole.
23 . The method of claim 22 , wherein the plasma is contacted for the period of 8 weeks to 48 weeks.
24 . The method of claim 22 , wherein the treatment provides an improvement in the patient's total SARA score of at least 0.8, or 0.9, or 1.0, or 1.1, or 1.2, or 1.3, or 1.4, or 1.5, or 1.6, or 1.7, or 1.8, or 1.9, or 2.0, or greater.